Division of Diabetes, Endocrinology & Metabolism, University of Nebraska Medical Center, Omaha, NE, USA.
J Diabetes Sci Technol. 2022 Jul;16(4):852-857. doi: 10.1177/19322968211037990. Epub 2021 Oct 12.
Despite advances in and increased adoption of technology, glycemic outcomes for individuals with type 1 diabetes (T1D) have not improved. Access to care is limited for many, in part due to a shortage of endocrinologists and their concentration in urban areas. Managing T1D via telehealth has potential to improve glycemic outcomes, as the barriers of travel-related time and cost are mitigated.
Our endocrine telehealth program started in 2013 and currently provides care to nine rural community hospitals in Nebraska and Iowa. A retrospective cohort study was performed to evaluate glycemic outcomes in people with T1D who received care at these telehealth clinics from 2013-2019. Data were collected on age, race, gender, prior diabetes provider, use of diabetes technology, and A1c values over time.
One hundred thirty-nine individuals were followed for an average duration of 32 months (range 4-69 months). Sixty-six percent of people were previously under the care of an endocrinologist. The most common therapeutic action, in addition to insulin adjustment, was addition of a CGM (52%). Each year in telemedicine care was associated with a decline of 0.13% in A1c (95% CI: -0.20, -0.06). There was no association between A1c and age or gender. When stratifying by previous diabetes provider, all groups had a statistically significant decline in A1c, even those with a previous endocrine provider. There was no statistically significant decline in A1c based on addition of technology.
We have shown that traditional telehealth visits are an effective way to provide care for people with T1D long-term and may provide distinct advantages to home telehealth visits.
尽管技术不断进步并得到广泛应用,但 1 型糖尿病(T1D)患者的血糖控制结果并未改善。由于内分泌专家短缺且集中在城市地区,许多人无法获得医疗服务。通过远程医疗来管理 T1D 具有改善血糖控制结果的潜力,因为旅行相关的时间和费用障碍得以减轻。
我们的内分泌远程医疗计划于 2013 年启动,目前为内布拉斯加州和爱荷华州的 9 家农村社区医院提供服务。我们进行了一项回顾性队列研究,以评估 2013 年至 2019 年间在这些远程医疗诊所接受治疗的 T1D 患者的血糖控制结果。收集的数据包括年龄、种族、性别、既往糖尿病提供者、糖尿病技术的使用情况以及 A1c 值随时间的变化情况。
共有 139 人接受了平均 32 个月(4-69 个月)的随访。66%的人之前曾接受过内分泌专家的治疗。除了胰岛素调整之外,最常见的治疗措施是添加 CGM(52%)。每年接受远程医疗护理与 A1c 下降 0.13%(95%CI:-0.20,-0.06)相关。A1c 与年龄或性别无关。按既往糖尿病提供者分层时,所有组的 A1c 均有统计学显著下降,即使是那些有既往内分泌提供者的组也是如此。根据技术的添加情况,A1c 没有统计学显著下降。
我们已经证明,传统的远程医疗访问是为 T1D 患者提供长期护理的有效方式,并且可能为家庭远程医疗访问提供明显优势。